Limited coverage criteria – methylphenidate extended-release

Last updated on March 19, 2025

 

Return to Special Authority drug list

Generic name

methylphenidate extended-release

Strength & form

18 mg/27 mg/36 mg/54 mg extended-release tablet

Special Authority criteria

Approval period

For the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older who require 12 hours of continuous coverage for hyperactivity, impulsivity, or inattention that interferes with functioning AND have been previously tried on one of the following with unsatisfactory results1 or intolerance:

  • Immediate‑release or sustained-release methylphenidate

OR

  • Immediate-release or sustained-release dextroamphetamine

Indefinite

Practitioner exemptions

  • None

Special notes

  • 1"Unsatisfactory results" is defined as no demonstrated effectiveness for symptoms of ADHD or functional impairment secondary to ADHD after a minimum 1 week trial of an adequate dose of immediate-release or sustained-release medication. Specific details of drug, dose and duration tried, and unsatisfactory response are required, as applicable

  • Coverage is not intended for "performance enhancement" in patients who do not have symptoms or functional impairment

Special Authority request form(s)